Nalaganje...

Deletion Mutations Keep Kinase Inhibitors in the Loop

Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Cell
Main Authors: Freed, Daniel M., Park, Jin H., Radhakrishnan, Ravi, Lemmon, Mark A.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5028821/
https://ncbi.nlm.nih.gov/pubmed/27070691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.03.017
Oznake: Označite
Brez oznak, prvi označite!